18325332. Systemic Delivery of Polypeptides simplified abstract (Massachusetts Institute of Technology)

Systemic Delivery of Polypeptides

Organization Name

Massachusetts Institute of Technology

Inventor(s)

Denitsa M. Milanova of Boston MA (US)

George M. Church of Brookline MA (US)

Noah Davidsohn of Brookline MA (US)

Carl Schoellhammer of Medford MA (US)

Robert S. Langer of Newton MA (US)

Anna I. Mandinova of Newton MA (US)

Carlo Giovanni Traverso of Newton MA (US)

Systemic Delivery of Polypeptides - A simplified explanation of the abstract

This abstract first appeared for US patent application 18325332 titled 'Systemic Delivery of Polypeptides

Simplified Explanation

The abstract describes a method for delivering a therapeutic polypeptide within a subject by genetically modifying skin cells using a genetically engineered virus to introduce a nucleic acid encoding the polypeptide for expression by the skin cells. The expressed polypeptide is then secreted by the skin cells and introduced into the subject's circulatory system.

• Genetically modified skin cells are created by introducing a genetically engineered virus.
• The virus delivers a nucleic acid encoding a therapeutic polypeptide for expression by the skin cells.
• The expressed polypeptide is secreted by the skin cells and enters the subject's circulatory system.

Potential Applications

This technology could be applied in the treatment of various diseases and conditions that require systemic delivery of therapeutic polypeptides, such as autoimmune disorders, genetic diseases, and cancer.

Problems Solved

This technology provides a non-invasive method for delivering therapeutic polypeptides systemically, avoiding the need for invasive procedures such as injections or infusions.

Benefits

The method offers a targeted and efficient way to deliver therapeutic polypeptides, potentially reducing side effects and improving patient outcomes. It also allows for continuous production and secretion of the polypeptide by the skin cells.

Potential Commercial Applications

This technology could be valuable in the development of novel therapies for a wide range of medical conditions, leading to potential commercialization in the pharmaceutical industry.

Possible Prior Art

Prior art may include similar methods of gene therapy or viral delivery systems for gene expression in cells, but the specific combination of genetically modified skin cells and systemic delivery of therapeutic polypeptides may be novel.

How does this method compare to traditional methods of delivering therapeutic polypeptides, such as injections or infusions?

This article does not provide a direct comparison between this method and traditional delivery methods, so it is unclear how the efficacy, safety, and cost-effectiveness of this approach stack up against existing practices.

What are the potential long-term effects of introducing genetically modified skin cells into a subject's body?

The article does not address the potential long-term implications or risks associated with introducing genetically modified skin cells into a subject, leaving questions about the safety and stability of this approach unanswered.

Original Abstract Submitted

A method for the systemic delivery of a polypeptide within a subject is provided by creating genetically modified skin cells via topical introduction of a genetically engineered virus which delivers a nucleic acid encoding a therapeutic polypeptide for expression by the skin cells, wherein the expressed therapeutic polypeptide is secreted by the skin cells and is introduced into the circulatory system of the subject.